Investigating a novel form of Charcot-Marie-Tooth disease
Investigating a novel form of Charcot-Marie-Tooth disease
批准号:
7991410
负责人:
SABRINA W YUM
金额:
$8.23万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-05-01 至 2012-04-30
关键词:
1 year oldAgeAge-MonthsAllelesAnimalsAxonBackBiopsyCaliberCervicalCharcot-Marie-Tooth DiseaseChildClinicalCultured CellsDataDevelopmentElectron MicroscopyEmployee StrikesFamilyFiberGenesGenotypeHumanIntermediate FilamentsInvestigationKnockout MiceLengthLightLumbar spinal cord structureMaintenanceMeasuresMissense MutationModelingMotorMusMutationMyelinNamesNerveNeural ConductionNeuropathyNodalNonsense MutationOptic NervePatientsPatternPeripheral NervesPlant RootsPlayProteinsProtocols documentationQuailRelative (related person)RoleSensorySpinal CordStudentsTestingTimeVentral RootsWorkaxonal degenerationbasedensityearly childhoodfallsfemoral nerveimmunocytochemistrylight microscopymutantneurofilamentneurophysiologynovelpublic health relevanceretinal rodssciatic nervesural nerve
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): We have identified a novel form of Charcot-Marie-Tooth disease (CMT) - the first family with a recessive mutation (E210X) in the NEFL gene, which encodes neurofilament light (NFL). Children homozygous for this mutation develop a progressive, severe, sensory and motor neuropathy with slow conduction well into the traditional "demyelinating range". We found that the mutant protein did not form intermediate filaments in cultured cells. The density of myelinated axons was markedly reduced, and the remaining axons were small and lacked intermediate filaments in a sural nerve biopsy from one patient by electron microscopy (EM). These findings indicate that the E210X mutation is likely a null allele, so that homozygous null alleles of NEFL cause a severe progressive neuropathy in humans. The latter conclusion was completely unexpected as the Nefl-null mice and quiver quail (which harbor a nonsense mutation in Nefl) were investigated and found not to have a neuropathy, in spite of the finding that myelinated PNS axons were devoid of neurofilaments (NFs) and failed to enlarge normally during development. This discrepancy prompted us to re-examine some "old" (at least one- year-old) Nefl-null mice with EM, which showed degenerating myelinated axons not only in peripheral nerves, but also in optic nerve and spinal cord, suggesting that NFL is required for the maintenance of myelinated axons in both PNS and CNS. However, these mice had been maintained an inbred line, so the possibility that other genes contributed to these pathological findings could not be excluded. To definitely examine this hypothesis, we propose to back crossing the mice to their former background (C57/Bl6) and compare age- matched Nelf -/-, Nelf , and Nelf littermates by examining the L4 and L5 ventral roots, sciatic, femoral and optic nerves, and cervical and lumbar spinal cord by light microscopy, immunocytochemistry and EM at 3, 6, 12, 18 and 24 months of age, with the following Specific Aims: 1) Determine the timing and pattern of axonal degeneration in the PNS of Nefl-null mice. 2) Investigate the cellular basis of slowed conduction in the PNS of Nefl-null mice. 3) Determine the timing and pattern of axonal degeneration in the CNS of Nefl-null mice. These data will establish whether NFs are essential for the maintenance of myelinated axons in both PNS and CNS; such a role has not been demonstrated in prior studies. If evidence of axonal degeneration is found, this model can be used for further investigation to determine why neurofilaments are required for axonal integrity and to understand the mechanism of axonal degeneration in these patients and perhaps patients with other kinds of CMT.
PUBLIC HEALTH RELEVANCE: The proposed study will establish whether NFs are essential for the maintenance of myelinated axons in both PNS and CNS; such a role has not been demonstrated in prior studies. If evidence of axonal degeneration is found, this model can be used for further investigation to determine why neurofilaments are required for axonal integrity and to understand the mechanism of axonal degeneration in these patients and perhaps patients with other kinds of CMT.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Investigating a novel form of Charcot-Marie-Tooth disease
-
批准号:8066275
-
项目类别:
-
资助金额:$8.06万
-
财政年份:2010
-
负责人:SABRINA W YUM
-
依托单位:
Dominant Connexin Mutations and Hearing Loss
-
批准号:7035819
-
项目类别:
-
资助金额:$18.99万
-
财政年份:2004
-
负责人:SABRINA W YUM
-
依托单位:
Dominant Connexin Mutations and Hearing Loss
-
批准号:7386544
-
项目类别:
-
资助金额:$15.98万
-
财政年份:2004
-
负责人:SABRINA W YUM
-
依托单位:
Dominant Connexin Mutations and Hearing Loss
-
批准号:7196448
-
项目类别:
-
资助金额:$19.23万
-
财政年份:2004
-
负责人:SABRINA W YUM
-
依托单位:
Dominant Connexin Mutations and Hearing Loss
-
批准号:6730169
-
项目类别:
-
资助金额:$19.04万
-
财政年份:2004
-
负责人:SABRINA W YUM
-
依托单位:
Dominant Connexin Mutations and Hearing Loss
-
批准号:6885373
-
项目类别:
-
资助金额:$18.92万
-
财政年份:2004
-
负责人:SABRINA W YUM
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: